<DOC>
	<DOCNO>NCT00979459</DOCNO>
	<brief_summary>This study assess pharmacokinetics two formulation MK-1006 . The primary hypothesis study MK-1006 area curve ( 0 infinity ) maximum concentration administration single 80 mg dose dry fill capsule ( DFC ) film coat tablet ( FCT ) formulation MK-1006 similar .</brief_summary>
	<brief_title>A Study Pharmacokinetics Two Formulations MK-1006 ( MK-1006-010 AM1 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<criteria>male female nonchild bear potential type 2 diabetes ( T2D ) either treat diet exercise alone single combination oral antihyperglycemic agent ( ) nonsmoker least 6 month history stroke , chronic seizure , major neurological disorder history major endocrine ( except T2D ) , gastrointestinal , cardiovascular , blood , liver , immune , kidney , respiratory , genitourinary abnormality diseases history cancer , except certain skin cervical cancer cancer successfully treat 10 year prior screen unstable rapidly progress diabetic retinopathy and/or neuropathy eye infection inflammation eye 2 week prior screen glaucoma blind incisional eye surgery last 6 month laser eye surgery last 3 month ( Lasik permit ) history type 1 diabetes symptomatic coronary artery disease consumes excessive amount alcohol and/or caffeine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>